Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment-Reference-Cited by-同舟云学术

Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment

Published:2017-01-30 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Kai Yugo,Hikita Hayato,Morishita Naoki,Murai Kazuhiro,Nakabori Tasuku,Iio Sadaharu,Hagiwara Hideki,Imai Yasuharu,Tamura Shinji,Tsutsui Syusaku,Naito Masafumi,Nishiuchi Meiko,Kondo Yasuteru,Kato Takanobu,Suemizu Hiroshi,Yamada Ryoko,Oze Tsugiko,Yakushijin Takayuki,Hiramatsu Naoki,Sakamori Ryotaro,Tatsumi Tomohide,Takehara Tetsuo

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep41660.pdf

Reference30 articles.

1. Liang, T. J. & Ghany, M. G. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 368, 1907–1917, doi: 10.1056/NEJMra1213651 (2013).

2. Manns, M. et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384, 1597–1605, doi: 10.1016/s0140-6736(14)61059-x (2014).

3. Kumada, H. et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 59, 2083–2091, doi: 10.1002/hep.27113 (2014).

4. Afdhal, N. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370, 1889–1898, doi: 10.1056/NEJMoa1402454 (2014).

5. Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370, 1483–1493, doi: 10.1056/NEJMoa1316366 (2014).

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. QoALa: a comprehensive workflow for viral quasispecies diversity comparison using long-read sequencing data;2024-07-18

2. Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors;Scientific Reports;2024-07-16

3. Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice;Liver Research;2023-03

4. Mammarenavirus Genetic Diversity and Its Biological Implications;Current Topics in Microbiology and Immunology;2023

5. Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia;Virus Research;2022-09